Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants

Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Overall Response Rate — 92 percentage of patients

Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria — 71; 82 percentage of…

Primary: Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review — 37.6; 22.7 weeks — p=0.012

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Objective Response Rate (CR + PR) — 46.7 percentage of participants

Primary: Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC) — 29.9 percentage of participants

Primary: Progression-Free Survival (PFS) — 8 years

Primary: Complete Response (CR) Rate — 0.68 proportion

Primary: Progression Free Survival (PFS) — 15.6; 6.2 Months — p=< 0.0001

Primary: Overall Response Rate (ORR) — 61 percentage of participants

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants

Primary: Progression-free Survival — 90 percentage of participants

Primary: Overall Response Rate (ORR) — 8.6 percentage of participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months

Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…

Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants

Primary: 3-year Progression-free Survival (PFS) — 63 % of pts progression-free survival

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Progression-Free Survival (PFS) — 4.8; 3.7; 1.8 months — p=<0.0001

Primary: Progression-free Survival Rate — 91; 78; 69 percentage of participants